1,3,5-三甲基-1H-吡唑-4-甲酸 | 1125-29-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1,3,5-三甲基-1H-吡唑-4-甲酸
• 中文别名: 1,3,5-三甲基-1H-吡唑-4-羧酸
• 英文名称: 1,3,5-trimethyl-1H-pyrazole-4-carboxylic acid
• 英文别名: 1,3,5-trimethylpyrazole-4-carboxylic acid；1.3.5-Trimethyl-pyrazol-carbonsaeure-(4)
• CAS: 1125-29-7
• 化学式: C₇H₁₀N₂O₂
• mdl: MFCD00159648
• 分子量: 154.169
• InChiKey: NOIOGQJFLIPRBI-UHFFFAOYSA-N

物化性质

• 熔点：
  215-217°C
• 沸点：
  297.6±35.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Name:	1 3 5-Trimethyl-1H-pyrazole-4-carboxylic acid 95+% Material Safety Data Sheet
Synonym:
CAS:	1125-29-7

Section 1 - Chemical Product MSDS Name:1 3 5-Trimethyl-1H-pyrazole-4-carboxylic acid 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1125-29-7	1,3,5-Trimethyl-1H-pyrazole-4-carboxyl	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1125-29-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 215 - 217 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H10N2O2
Molecular Weight: 154

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1125-29-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1125-29-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1125-29-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1125-29-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3,5-三甲基-1H-吡唑-4-甲酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 1,3,5-三甲基-1H-吡唑-4-羰酰氯
  参考文献：
  名称：

  一种杀螨剂Pyf lubumide的合成方法

  摘要：

  本发明公开了一种杀螨剂Pyflubumide的合成方法。本发明所用的原料价廉易得，合成路线简便、高效。本发明特别之处是能够选择性的对3‑异丁基‑4‑(2'‑羟基六氟异丙基)芳胺II的羟基进行甲基化，关键中间体3‑异丁基‑4‑(2'‑甲氧基六氟异丙基)芳胺III的合成具有显著的优势和效率，本发明提供的合成杀螨剂Pyflubumide的方法简便、高效、低成本，是一种易于工业化的新方法。

  公开号：

  CN111825616A
• 作为产物：
  描述：

  1,3,5-三甲基-1H-吡唑-4-羰酰氯 在 水 作用下， 反应 5.0h， 生成 1,3,5-三甲基-1H-吡唑-4-甲酸
  参考文献：
  名称：

  The Direct Carboxylation of Pyrazoles

  摘要：

  DOI：

  10.1055/s-1986-31885

文献信息

• COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS
  申请人：Nantbio, Inc.

  公开号：US20180201610A1

  公开（公告）日：2018-07-19

  Compounds and compositions are presented that inhibit K-Ras, and especially mutant K-Ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.

  提供了抑制K-Ras的化合物和组合物，特别是突变型K-Ras。某些化合物优先甚至选择性地抑制特定形式的突变型K-Ras，特别是G12D突变形式。
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。
• Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents
  作者：Masao Yoshida、Ichiro Hayakawa、Noriyuki Hayashi、Toshinori Agatsuma、Youko Oda、Fumie Tanzawa、Shiho Iwasaki、Kumiko Koyama、Hidehiko Furukawa、Shinichi Kurakata、Yuichi Sugano

  DOI：10.1016/j.bmcl.2005.05.077

  日期：2005.7

  cytotoxicity against tumorigenic cell lines, 2,6-dichloro-N-[2-(cyclopropanecarbonylamino)benzothiazol-6-yl]benzamide (13b) was designed and synthesized as a biologically stable derivative containing no nitro group. The highly potent derivative 13b exhibited excellent in vivo inhibitory effect on tumor growth.

  基于2-甲基-4-硝基-2H-吡唑-3-羧酸[2-（环己烷羰基氨基）苯并噻唑-6-基]酰胺（1），该化合物对致瘤细胞系2,6-二氯-将N- [2-（环丙烷羰基氨基）苯并噻唑-6-基]苯甲酰胺（13b）设计并合成为不含硝基的生物稳定衍生物。高效衍生物13b对肿瘤生长表现出优异的体内抑制作用。
• Kinase Inhibitors
  申请人：Wurster A. Julie

  公开号：US20070032478A1

  公开（公告）日：2007-02-08

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors
  作者：Mark Zak、Po-wai Yuen、Xiongcai Liu、Snahel Patel、Deepak Sampath、Jason Oeh、Bianca M. Liederer、Weiru Wang、Thomas O’Brien、Yang Xiao、Nicholas Skelton、Rongbao Hua、Jasleen Sodhi、Yunli Wang、Lei Zhang、Guiling Zhao、Xiaozhang Zheng、Yen-Ching Ho、Kenneth W. Bair、Peter S. Dragovich

  DOI：10.1021/acs.jmedchem.6b00697

  日期：2016.9.22

  NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent

  NAMPT抑制剂可能显示出作为肿瘤治疗剂的潜力。在整个NAMPT抑制剂计划中，我们发现在抑制剂左手侧暴露的吡啶或相关杂环系统是有效抑制细胞NAMPT的必要药效团。但是，当在抑制剂中心与苄基结合时，此类吡啶样部分也导致对CYP2C9的持续且有效的抑制。为了减少CYP2C9的抑制作用，使用了一种平行合成方法来鉴定Fsp3含量增加的中央苄基取代基。因此，发现了一个螺环的中心基序，该基序与左手的吡啶（或吡啶样系统）结合，可提供对细胞有效的NAMPT抑制剂，并具有最小的CYP2C9抑制作用。68，一种高效的NAMPT抑制剂，在小鼠肿瘤异种移植模型中具有出色的功效，并且在所测试的浓度下缺乏可测量的CYP2C9抑制作用。